Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Universitat Pompeu Fabra. Barcelona Institute for Global Health. ISGlobal. Barcelona, Spain / Faculdade de Medicina. Hospital das Clínicas. Heart Institute. Pulmonary Division. São Paulo, SP, Brazil / CIBER Epidemiología y Salud Pública (CIBERESP). Madrid, Spain.
University of Florida. College of Public Health & Health Professions. Department of Biostatistics. Gainesville, FL, USA.
Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à Covid-19. Brasília, DF, Brasil.
Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brazil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Secretary of Manaus. Municipal Health. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil.
Pan American Health Organization, Brasilia, DF, Brazil.
Pan American Health Organization, Brasilia, DF, Brazil.
Pan American Health Organization, Brasilia, DF, Brazil.
State University of Mato Grosso do Sul, Dourados, MS, Brazil.
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute, Gainesville, FL, USA.
Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics, Atlanta, GA, USA.
Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, testnegative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

Publisher

Nature

Citation

RANZANI, Otavio T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron in Brazil. Nature Communications, p. 1-10, 2022.

DOI

10.1038/s41467-022-33169-0

Notes

These authors contributed equally: Derek A. T. Cummings, Natalie E Dean, Jason R. Andrews, Albert I. Ko, Julio Croda.

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/56134

Type

Copyright

Open access

Sustainable Development Goals

Collections

Share

Statistics

Metadata

Author

Affilliation

Abstract

Keywords in Portuguese

Keywords

DeCS

Publisher

Nature

Citation

DOI

Notes